Associations - Ameile (aumolertinib)

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1	aumolertinib Sensitive: A1 - Approval aumolertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2	bevacizumab + aumolertinib Sensitive: C2 – Inclusion Criteria bevacizumab + aumolertinib Sensitive : C2
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2	aumolertinib + HS-10241 Sensitive: C2 – Inclusion Criteria aumolertinib + HS-10241 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2	anlotinib + aumolertinib Sensitive: C2 – Inclusion Criteria anlotinib + aumolertinib Sensitive : C2
EGFR positive	Non Small Cell Lung Cancer	EGFR positive	Non Small Cell Lung Cancer	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR exon 19 deletion + TP53 mutation + MET amplification	Non Small Cell Lung Cancer	EGFR exon 19 deletion + TP53 mutation + MET amplification	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3	icotinib + aumolertinib Sensitive: C3 – Early Trials icotinib + aumolertinib Sensitive : C3
PD-L1 underexpression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 underexpression + EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	EGFR mutation + PIK3CA mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR G719X + EGFR L861Q + EGFR S768I	Non Small Cell Lung Cancer	EGFR G719X + EGFR L861Q + EGFR S768I	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	aumolertinib + HS-10241 Sensitive: C3 – Early Trials aumolertinib + HS-10241 Sensitive : C3	aumolertinib + HS-10241 Sensitive: C3 – Early Trials aumolertinib + HS-10241 Sensitive : C3
EGFR L858R + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR L858R + EGFR exon 19 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR L858R + EGFR exon 21 deletion	Non Small Cell Lung Cancer	EGFR L858R + EGFR exon 21 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3
EGFR T790M negative	Non Small Cell Lung Cancer	EGFR T790M negative	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR L858R + EGFR T790M	Lung Adenocarcinoma	EGFR L858R + EGFR T790M	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4
EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4
EGFR L858R	Glioblastoma	EGFR L858R	Glioblastoma	anlotinib + temozolomide + aumolertinib Sensitive: C4 – Case Studies anlotinib + temozolomide + aumolertinib Sensitive : C4	anlotinib + temozolomide + aumolertinib Sensitive: C4 – Case Studies anlotinib + temozolomide + aumolertinib Sensitive : C4
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4	aumolertinib Sensitive: C4 – Case Studies aumolertinib Sensitive : C4

Ameile (aumolertinib)

Associations
(39)

Associations
(39)

Ameile (aumolertinib)

Associations(39)

Associations(39)

Associations
(39)

Associations
(39)